Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
作者信息
Hellmann K, Ryall R D, Macdonald E, Newton K A, James S E, Jones S
出版信息
Cancer. 1978 Jan;41(1):100-7. doi: 10.1002/1097-0142(197801)41:1<100::aid-cncr2820410115>3.0.co;2-p.
Abstract
Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination. No increase in tissue reactions or adverse side-effects (apart from a readily reversible leukopenia) was observed. The implication is that razoxane acts as a well tolerated adjuvant for radiotherapy.
摘要
Zotero 插件